LDHA, lactate dehydrogenase A, 3939

N. diseases: 185; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 GeneticVariation group BEFREE Warburg effect is characterized by the upregulation of HIF-1 and c-Myc regulated LDH-A, even aerobically owing to hypoxic environment and alterations in oncogenes or tumor suppressor genes in cancer. 29866021 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 GeneticVariation group BEFREE Clinical, translational and experimental data supporting the uniqueness of the LDHA gene and its product LDH5 isoenzyme are summarized and future directions for a metabolic treatment of cancer are highlighted. 29913092 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 GeneticVariation group BEFREE Inhibition of LDH activity by small hairpin ribonucleic acid or expression of phospho-deficient LDHA Y10F sensitized the cancer cells to anoikis induction and resulted in attenuated cell invasion and elevated reactive oxygen species, whereas such phenotypes were reversed by its product lactate or antioxidant N-acetylcysteine, suggesting that Y10 phosphorylation-mediated LDHA activity promotes cancer cell invasion and anoikis resistance through redox homeostasis. 28218905 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 GeneticVariation phenotype BEFREE In addition, LDHA knockdown or LDHA Y10F rescue expression in human cancer cells resulted in decreased tumour metastasis in xenograft mice. 28218905 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 GeneticVariation phenotype BEFREE These changes resulted in a greater delay in metastases formation and 40% long-term survivors (>20 weeks) in the LDH-A KD cohort following surgical resection of the primary tumor. 30248111 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 GeneticVariation group BEFREE However, LDHA expression in human brain metastases was not associated with the number of tumors, BRAF(V600E) status, or survival. 25791837 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 GeneticVariation group BEFREE These changes resulted in a greater delay in metastases formation and 40% long-term survivors (>20 weeks) in the LDH-A KD cohort following surgical resection of the primary tumor. 30248111 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 GeneticVariation phenotype BEFREE Cancer cell migration and invasion increased due to LDHA elevation of the altered metabolic axis driven by activated CK2. 30926903 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE Inhibition of LDH activity by small hairpin ribonucleic acid or expression of phospho-deficient LDHA Y10F sensitized the cancer cells to anoikis induction and resulted in attenuated cell invasion and elevated reactive oxygen species, whereas such phenotypes were reversed by its product lactate or antioxidant N-acetylcysteine, suggesting that Y10 phosphorylation-mediated LDHA activity promotes cancer cell invasion and anoikis resistance through redox homeostasis. 28218905 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE Warburg effect is characterized by the upregulation of HIF-1 and c-Myc regulated LDH-A, even aerobically owing to hypoxic environment and alterations in oncogenes or tumor suppressor genes in cancer. 29866021 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE Clinical, translational and experimental data supporting the uniqueness of the LDHA gene and its product LDH5 isoenzyme are summarized and future directions for a metabolic treatment of cancer are highlighted. 29913092 2019
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.050 GeneticVariation group BEFREE These changes resulted in a greater delay in metastases formation and 40% long-term survivors (>20 weeks) in the LDH-A KD cohort following surgical resection of the primary tumor. 30248111 2018
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.050 GeneticVariation group BEFREE In addition, LDHA knockdown or LDHA Y10F rescue expression in human cancer cells resulted in decreased tumour metastasis in xenograft mice. 28218905 2017
CUI: C0037284
Disease: Skin lesion
Skin lesion 		0.020 GeneticVariation group BEFREE Erythematosquamous skin lesions in hereditary lactate dehydrogenase M-subunit deficiency. 3789777 1986
CUI: C0030319
Disease: Panic Disorder
Panic Disorder 		0.010 GeneticVariation disease BEFREE But, comparison of LDHA exon 5 genotypes in PD probands (n = 25) to that of random newborn controls (n = 182) did not demonstrate any significant differences. 12555229 2003
CUI: C2931743
Disease: Lactate dehydrogenase deficiency type A
Lactate dehydrogenase deficiency type A 		0.600 Biomarker disease GENOMICS_ENGLAND Estimation of the gene frequency of lactate dehydrogenase subunit deficiencies. 6517049 1984
CUI: C2931743
Disease: Lactate dehydrogenase deficiency type A
Lactate dehydrogenase deficiency type A 		0.600 Biomarker disease CTD_human
CUI: C2931743
Disease: Lactate dehydrogenase deficiency type A
Lactate dehydrogenase deficiency type A 		0.600 Biomarker disease GENOMICS_ENGLAND Analysis of genetic mutations in human lactate dehydrogenase-A(M) deficiency using DNA conformation polymorphism in combination with polyacrylamide gradient gel and silver staining. 1953713 1991
CUI: C2931743
Disease: Lactate dehydrogenase deficiency type A
Lactate dehydrogenase deficiency type A 		0.600 Biomarker disease GENOMICS_ENGLAND Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. 27604308 2016
CUI: C0027080
Disease: Myoglobinuria
Myoglobinuria 		0.400 Biomarker phenotype HPO
CUI: C0027080
Disease: Myoglobinuria
Myoglobinuria 		0.400 Biomarker phenotype CTD_human Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. 21332213 2011
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.380 Biomarker disease CTD_human MTOR inhibitor-based combination therapies for pancreatic cancer. 29384525 2018
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.380 Biomarker disease BEFREE Taken together, our findings highlight p53 status in pancreatic cancer as a biomarker to predict sensitivity to LDH-A inhibition, with regard to both real-time noninvasive imaging by 13C MRS as well as therapeutic response. 26113084 2015
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.380 Biomarker disease BEFREE Taken together, our study revealed the oncogenic role of LDHA in pancreatic cancer and suggested that LDHA might be a potential therapeutic target. 23404405 2013
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.380 Biomarker disease BEFREE The targeting of glycolytic enzymes such as PKM2 and LDHA represents a promising therapeutic approach for the treatment of pancreatic cancer. 31527446 2019